Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014 (2014), Article ID 603409, 7 pages
http://dx.doi.org/10.1155/2014/603409
Research Article

Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis

1Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China
2Department of Hematology and Oncology, Chongqing the Third Hospital, Chongqing 400014, China
3Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China

Received 19 August 2013; Accepted 18 October 2013; Published 14 January 2014

Academic Editors: K. D. Burns and D. M. Coldwell

Copyright © 2014 Wei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J.-G. Fan and G. C. Farrell, “Epidemiology of non-alcoholic fatty liver disease in China,” Journal of Hepatology, vol. 50, no. 1, pp. 204–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. C. Leite, C. A. Villela-Nogueira, V. L. N. Pannain et al., “Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors,” Liver International, vol. 31, no. 5, pp. 700–706, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Cohen, J. D. Horton, and H. H. Hobbs, “Human fatty liver disease: old questions and new insights,” Science, vol. 332, no. 6037, pp. 1519–1523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Yki-Järvinen, “Thiazolidinediones and the liver in humans,” Current Opinion in Lipidology, vol. 20, no. 6, pp. 477–483, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. A. Sarafidis, A. N. Lasaridis, P. M. Nilsson et al., “Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase,” Journal of Hypertension, vol. 22, no. 9, pp. 1769–1777, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Rszer and M. Ricote, “PPARs in the renal regulation of systemic blood pressure,” PPAR Research, vol. 2010, Article ID 698730, 11 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Matthew Morris, J. A. Fletcher, J. P. Thyfault et al., “The role of angiotensin II in nonalcoholic steatohepatitis,” Molecular and Cellular Endocrinology, vol. 378, no. 1-2, pp. 29–40, 2013. View at Google Scholar
  8. M. Donoghue, F. Hsieh, E. Baronas et al., “A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9,” Circulation Research, vol. 87, no. 5, pp. E1–E9, 2000. View at Google Scholar · View at Scopus
  9. R. A. S. Santos, A. C. Simoes e Silva, C. Maric et al., “Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8258–8263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D.-F. Gao, X.-L. Niu, G.-H. Hao et al., “Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells–Role of PPAR-γ in vascular fibrosis,” Biochemical Pharmacology, vol. 73, no. 2, pp. 185–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Paizis, C. Tikellis, M. E. Cooper et al., “Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2,” Gut, vol. 54, no. 12, pp. 1790–1796, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Gembardt, A. Sterner-Kock, H. Imboden et al., “Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents,” Peptides, vol. 26, no. 7, pp. 1270–1277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Fernandes, N. Y. Hashimoto, and E. M. Oliveira, “Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats,” Brazilian Journal of Medical and Biological Research, vol. 43, no. 9, pp. 837–842, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Gupte, C. M. Boustany-Kari, K. Bharadwaj et al., “ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 295, no. 3, pp. R781–R788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Y. Lee, E. Y. Lee, B. J. Lee et al., “Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats,” Yonsei Medical Journal, vol. 48, no. 2, pp. 301–307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. D. E. Kleiner, E. M. Brunt, M. van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Google Scholar · View at Scopus
  18. Z.-J. Xu, J.-G. Fan, X.-D. Ding, L. Qiao, and G.-L. Wang, “Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats,” Digestive Diseases and Sciences, vol. 55, no. 4, pp. 931–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. C. B. Herath, F. J. Warner, J. S. Lubel et al., “Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis,” Journal of Hepatology, vol. 47, no. 3, pp. 387–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. M. Boustany, K. Bharadwaj, A. Daugherty, D. R. Brown, D. C. Randall, and L. A. Cassis, “Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 287, no. 4, pp. R943–R949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Rahmouni, A. L. Mark, W. G. Haynes, and C. D. Sigmund, “Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity,” American Journal of Physiology—Endocrinology and Metabolism, vol. 286, no. 6, pp. E891–E895, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Engeli, J. Böhnke, K. Gorzelniak et al., “Weight loss and the renin-angiotensin-aldosterone system,” Hypertension, vol. 45, no. 3, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Bertile and T. Raclot, “Differences in mRNA expression of adipocyte-derived factors in response to fasting, refeeding and leptin,” Biochimica et Biophysica Acta, vol. 1683, no. 1–3, pp. 101–109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. F. H. Einstein, G. Atzmon, X.-M. Yang et al., “Differential responses of visceral and subcutaneous fat depots to nutrients,” Diabetes, vol. 54, no. 3, pp. 672–678, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. B. Mayerson, R. S. Hundal, S. Dufour et al., “The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes,” Diabetes, vol. 51, no. 3, pp. 797–802, 2002. View at Google Scholar · View at Scopus
  27. M.-L. Huang, X. Li, Y. Meng et al., “Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors,” Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 1, pp. e1–e6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. C. M. Ferrario, J. Jessup, M. C. Chappell et al., “Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2,” Circulation, vol. 111, no. 20, pp. 2605–2610, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Zhang, Z.-Z. Li, D.-F. Liu, X. Xu, Z.-C. Mei, and W. Shen, “Angiotensin-converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumour necrosis factor-α, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 7, pp. 631–636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. F. Georgescu, R. Ionescu, M. Niculescu, L. Mogoanta, and L. Vancica, “Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis,” World Journal of Gastroenterology, vol. 15, no. 8, pp. 942–954, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Olivares-Reyes, A. Arellano-Plancarte, and J. R. Castillo-Hernandez, “Angiotensin II and the development of insulin resistance: implications for diabetes,” Molecular and Cellular Endocrinology, vol. 302, no. 2, pp. 128–139, 2009. View at Publisher · View at Google Scholar · View at Scopus